Natalia Paola Espinosa

Ms. Natalia Paola Espinosa


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAliyah Lyam Bocachica Adorno
Aliyah Lyam Bocachica Adorno
AAAdriana Y. Aponte-Ramos
Adriana Y. Aponte-Ramos
PRPaola Sofía Rivera-Fuentes
Paola Sofía Rivera-Fuentes
NENatalia Paola Espinosa
Natalia Paola Espinosa
LUZ V. ARROYO-CRUZLUZ V. ARROYO-CRUZ
LUZ V. ARROYO-CRUZ
Michelle M. Martinez-MontemayorMichelle M. Martinez-Montemayor
Michelle M. Martinez-Montemayor
Ergosterol peroxide (EP) triggers apoptosis pathways by inducing reactive oxygen species (ROS) in TNBC cell lines. Excess ROS production is associated with major damage to mitochondria. We hypothesized that EP may act through ROS-induced mitochondrial dysfunction. Therefore, we performed a series of assays that assessed mitochondrial membrane potential (MMP), cellular respiration, and glycolysis in TNBC models. Cardiomyocytes derived from human-induced pluripotent stem cells were chosen as a non-cancerous model because of their high mitochondrial content. Two in vivo TNBC models were used to quantify the effect of EP on tumor volume and metastases. EP reduced MMP and disrupted mitochondrial functions exclusively in TNBC cells. In vivo EP was effective in reducing tumor volume without affecting liver function. There was also a significant decrease in metastasis to the lung, liver, and cancer stem cells following treatment. These results suggest EP is a promising therapy for TNBC.

11 November 2023 in Life
Verified
Journal Article
Open access
PDF file
ASAndres De Freitas Suarez
Andres De Freitas Suarez
NENatalia Paola Espinosa
Natalia Paola Espinosa
NANatalia Alvarez-Roger
Natalia Alvarez-Roger
ACArianna Iris Cabrera-Suarez
Arianna Iris Cabrera-Suarez
GJGuillermo Jiménez-Jordán
Guillermo Jiménez-Jordán
JAJanaina Maria Alves
Janaina Maria Alves
HIV-associated neurocognitive disorders (HANDs) continue to impact patients despite antiretroviral therapy. A combination of antiretroviral therapies can diminish the HIV viral load to near undetectable levels, but fails to preserve neurocognitive integrity. The cytokine leukemia inhibitory factor (LIF) has shown neuroprotective properties that could mitigate neurodegeneration in HANDs. The LIF promotes neurogenesis, neural cell differentiation, and survival. Combination antiretroviral therapy reduces severe forms of HANDs, but neurocognitive impairment persists; additionally, some antiretrovirals have additional adverse neurotoxic effects. The LIF counteracts neurotoxic viral proteins and limits neural cell damage in models of neuroinflammation. Adding the LIF as an adjuvant therapy to enhance neuroprotection merits further research for managing HANDs. The successful implementation of the LIF to current therapies would contribute to achieving a better quality of life for the affected population.